Navidea Biopharmaceuticals to Present at Biotech Showcase 2018
December 19 2017 - 4:05PM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a company
focused on the development of precision immunodiagnostic agents and
immunotherapeutics, today announced that it will be presenting
at the Biotech Showcase in San Francisco, CA being held on January
8-10, 2018. Dr. Michael Goldberg, Chief Executive Officer of
Navidea, will be giving a presentation and meeting with
investors.
Event: Biotech
Showcase™Presentation Date: Monday, January 8,
2018Presentation Time: 10:00 am PTLocation: Hilton
San Francisco Union Square, San Francisco, CA
For investors attending the Biotech Showcase, please contact
Navidea Investor Relations to schedule a meeting with management
at tpatel@edisongroup.com.
The presentation will be webcast live and remain available for
90 days following the presentation. To access the webcast, please
visit the Investors presentations tab of the Investors section of
the Navidea website at www.navidea.com.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is
developing multiple precision-targeted products based on its
Manocept™ platform to enhance patient care by identifying the sites
and pathways of disease and enable better diagnostic accuracy,
clinical decision-making, and targeted treatment. Navidea’s
Manocept platform is predicated on the ability to specifically
target the CD206 mannose receptor expressed on activated
macrophages. The Manocept platform serves as the molecular backbone
of Tc 99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. The development
activities of the Manocept immunotherapeutic platform are being
conducted by Navidea in conjunction with its subsidiary, Macrophage
Therapeutics, Inc. Navidea’s strategy is to deliver superior growth
and shareholder return by bringing to market novel products and
advancing the Company’s pipeline through global partnering and
commercialization efforts.
For more information, please visit www.navidea.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171219006195/en/
Navidea Biopharmaceuticals, Inc.Jed Latkin,
614-551-3416CFO/COOjlatkin@navidea.comorEdison AdvisorsTirth Patel,
646-653-7035Vice President, Investor
Relationstpatel@edisongroup.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Sep 2023 to Sep 2024